Safety and Tolerability The safety profile of GLP-1 receptor agonists is well-established
The part many people miss is that lean mass on a body composition scan is not just muscle tissue
Gastrointestinal side effects make up around half of the side effects reported to the MHRA via the Yellow Card Scheme for tirzepatide, semaglutide and liraglutide between 2020 and 2025 (43,475 out of 78,171 side effects
FDAs Concerns with Unapproved GLP-1 Drugs Used for Weight Loss Compounding and the FDA: Questions and Answers Understanding unapproved versions of these drugs FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 (glucagon-like peptide-1 (GLP-1) receptor agonists) drugs, including semaglutide and tirzepatide, as an option for weight loss
FoxO promotes the expression of atrophy-related genes (atrogenes), and under critical conditions such as sepsis, decreased IGF-1-PI3K-Akt-mTOR signaling increases FoxO-mediated expression of atrogenes, reducing protein synthesis (81-83)
Mistake 2: Using the wrong water Bacteriostatic water is not just any sterile water